Results 11 to 20 of about 581 (108)

Treatment of basal cell carcinoma with Sonidegib and literature review

Pifu-xingbing zhenliaoxue zazhi
Objective To investigate the efficacy and safety of Sonidegib for basal cell carcinoma. Methods Clinical data and skin histology were analyzed in a patient with ulcerated brown plaque on the nasal dorsum.
Ziyue JIA, Zhe ZHUANG, Xinhui LI, Yongfeng CHEN   +3 more
doaj   +2 more sources

Trichoscopy and LC-OCT findings in sonidegib-induced alopecia in patients with advanced basal cell carcinoma [PDF]

Dermatology Reports
Sonidegib is a Hedgehog pathway inhibitor (HHIs) used as first-line systemic treatment for patients with advanced basal cell carcinoma (aBCC). Alopecia is reported as a frequent adverse event (AE), occurring in 49% of patients. Forty-five patients with
Irina Ciobotariu, Gerardo Palmisano, Giacomo Caldarola, Alfredo Piccerillo, Francesco Tassone, Simone Cappilli, Alessandro Di Stefani, Ketty Peris   +7 more
doaj   +3 more sources

Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study [PDF]

Dermatology Reports
Vismodegib and sonidegib are smoothened (SMO) inhibitors approved for the treatment of advanced basal cell carcinoma (aBCC). This study investigates the real-world experiences and outcomes associated with these therapies across multiple Italian centers ...
Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò   +9 more
doaj   +2 more sources

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma [PDF]

Frontiers in Oncology, 2020
Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare workload burden is substantial within dermatology departments. Although most BCCs are small, well-defined tumors amenable of surgery or conservative procedures, in a ...
Gabriella Brancaccio, Federico Pea, Federico Pea, Elvira Moscarella, Giuseppe Argenziano   +4 more
doaj   +2 more sources

Sonidegib Inhibits the Adhesion of Acute Myeloid Leukemia to the Bone Marrow in Hypoxia: An Optical Tweezer Study

Biomedicines
Background: Acute myeloid leukemia (AML) is a heterogeneous disease highly resistant to chemotherapeutic agents. Leukemia stem cells (LSCs) can enter a dormant state and avoid apoptosis in the protective niche of the bone marrow (BM) microenvironment ...
Katarzyna Gdesz-Birula, Sławomir Drobczyński, Krystian Sarat, Kamila Duś-Szachniewicz   +3 more
doaj   +2 more sources

Locally advanced basal cell carcinoma: Real-life data with sonidegib [PDF]

, 2022
In recent years, the category of hedgehog pathway inhibitor (HHI) has shown great results in patients with advanced basal cell carcinoma (aBCC), but few real-life data on efficacy and safety profile of sonidegib are available. We report our management of
Zelin, Enrico, Conforti, Claudio, Vezzoni, Roberta, Toffoli, Ludovica, Zalaudek, Iris, Agozzino, Marina, di Meo, Nicola, Enrico Zelin, Ludovica Toffoli, Claudio Conforti, Nicola di Meo, Marina Agozzino, Iris Zalaudek, Roberta Vezzoni   +13 more
core   +1 more source

Sonidegib Suppresses Production of Inflammatory Mediators and Cell Migration in BV2 Microglial Cells and Mice Treated with Lipopolysaccharide via JNK and NF-κB Inhibition

, 2022
Our structure-based virtual screening of the FDA-approved drug library has revealed that sonidegib, a smoothened antagonist clinically used to treat basal cell carcinoma, is a potential c-Jun N-terminal kinase 3 (JNK3) inhibitor.
Nguyen, Ngoc Minh, Men Thi Hoai Duong, Duong, Men Thi Hoai, Bui, Bich Phuong, Ahn, Hee-Chul, Nguyen, Phuong Linh, Chen, Xiaozhen, Jungsook Cho, Cho, Jungsook, Ngoc Minh Nguyen, Phuong Linh Nguyen, Xiaozhen Chen, Bich Phuong Bui, Hee-Chul Ahn   +13 more
core   +1 more source

Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas

, 2021
Locally advanced basal cell carcinoma (laBCC) represents a rare but possible occurrence in the vast scenario of dermatological diseases. It is well known that most BCC has a pathological activation of the hedgehog pathway, making them susceptible to ...
Veronese F., Savoia P., Gironi L. C., Zavattaro E., Tarantino V.   +4 more
core   +1 more source

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study [PDF]

, 2020
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of the ...
Loquai, C, Schulze, H‐J, Kudchadkar, R, Migden, M R, Squittieri, N, Lear, J T, Combemale, P, Trefzer, U, Gutzmer, R, Lewis, K D, Dummer, Reinhard; https://orcid.org/, Guminksi, A, Stratigos, A J, Chang, A L S; https://orcid.org/, Dirix, L, Kaatz, M, Plummer, R, Schulze HJ, Dirix L, Dummer R, Combemale P, Kudchadkar R, Loquai C, Chang ALS, Plummer R, Kaatz M, Guminksi A, Lear JT, Stratigos AJ, Squittieri N, Lewis KD, Gutzmer R, Trefzer U, Migden MR   +33 more
core   +3 more sources

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial [PDF]

, 2021
Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma.
Dummer, Reinhard; https://orcid.org/, Migden, Michael, Guminski, Alexander, Lewis, Karl; https://orcid.org/, Squittieri, Nicholas, Farberg, Aaron S, Reinhard Dummer, Aaron S. Farberg, Nicholas Squittieri, Karl Lewis, Alexander Guminski, Michael Migden   +11 more
core   +1 more source